Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study

Jung, Yoon Suk; Han, Minkyung; Kim, Jae Hak; Park, So Hee; Cheon, Jae Hee

doi:10.1007/s10620-017-4640-9

Cited by 62 publications

(89 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To increase the diagnostic accuracy of IBD, we enrolled only patients whose records showed a prescription for IBD medicine as well as an appropriate diagnostic code . Specifically, the ICD‐10 codes K51.0–51.9 denoted UC, and the ICD‐10 codes K50.0–50.9 indicated CD.…”

Section: Methodsmentioning

confidence: 99%

“…Regarding prescriptions, 5‐ASA, immunomodulators (azathioprine or 6‐mercaptopurine), or biologics (infliximab or adalimumab) were defined as IBD medications. More specifically, prescription of an IBD medication was defined as the prescription of 5‐ASA for 1 month, immunomodulators at least once, and/or biologics at least once . During the study period (between 2010 and 2016), infliximab and adalimumab were biologics approved for the treatment of patients with CD and UC in South Korea.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases

Han

Jung

Cheon

et al. 2019

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aim Variation in medical care can be an obstacle to improving quality and outcome of treatment. We conducted a nationwide, population‐based study to identify regional variations in medication prescription rates in Korean patients with inflammatory bowel diseases (IBDs). Methods Using the National Health Insurance claims, we collected data on patients diagnosed with IBD (8974 cases of Crohn's disease [CD] and 17 167 cases of ulcerative colitis [UC]) between 2010 and 2016. Results Overall rates of biologics (infliximab or adalimumab) use in CD and UC were 19.6% and 6.1%, respectively, and those of immunomodulator (azathioprine or 6‐mercaptopurine) use were 66.9% and 20.4%, respectively. The average periods from diagnosis to first biologics use for CD and UC were 1.6 and 1.8 years, respectively, and those of immunomodulators were 0.6 and 1.3 years, respectively. In Seoul, Daegu, and Busan, three major cities in Korea, biologics prescription rates for CD were 20.7%, 22.9%, and 14.6%, respectively, and those for UC were 7.3%, 6.7%, and 4.5%, respectively. In the top 7 regions with the highest number of patients in Seoul, there were 3.6‐fold and 3.2‐fold variations between regions with the highest and lowest frequency of biologics use in CD and UC, respectively. In addition, there were 1.6‐fold and 2.8‐fold variations between regions with the highest and lowest frequency of immunomodulator use for CD and UC, respectively. Conclusions Regional variation exists in medication prescription rates within a single city as well as nationwide, suggesting that standardization of IBD treatment is necessary in Korea.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases

Han

Jung

Cheon

et al. 2019

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Health Insurance Review and Assessment Service (HIRA) operates under the Korean NHIS and contains the adjusted medical and pharmacy claims data for the entire Korean population . For this reason, its database has been used for many epidemiological studies . Specifically, the HIRA database provides data regarding each de‐identified individual's sociodemographic characteristics (sex, age, and medical‐aid program), health‐care service information (e.g.…”

Section: Methodsmentioning

confidence: 99%

“…Specifically, the HIRA database provides data regarding each de‐identified individual's sociodemographic characteristics (sex, age, and medical‐aid program), health‐care service information (e.g. diagnoses, procedures, prescriptions, and type of health‐care service provider), and claim dates . The HIRA database diagnostic codes were established using the sixth edition of the Korean Classification of Disease, which is a version of the International Classification of Disease 10th revision (ICD‐10) modified for the Korean health‐care system .…”

Section: Methodsmentioning

confidence: 99%

“…The database contains billing data provided by physicians and pharmacists, including data regarding services performed, admissions, diagnoses, procedures, discharge statuses, and patient demographics. It has been used for nationwide, population‐based studies of various diseases and for investigations into rare disease trends or statuses, including IBD . Despite its strengths, the nature of the data hinders the accuracy of the operational definitions for disease diagnoses in real practice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Emerging trends of inflammatory bowel disease in South Korea: A nationwide population‐based study

Kwak

Myung

Lee

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Little is known regarding the exact burden of inflammatory bowel disease (IBD) in Asian countries because previous epidemiologic studies were hospital based. We aimed to develop and validate an operational definition of IBD cases from health insurance claims data and to examine the epidemiological features of IBD in Korea. Methods We analyzed stratified sample data from the Korean Health Insurance Review and Assessment (2010–2016) database using 12 different definitions and applied the best definition to the entire (2007–2016) dataset. Results The definition that combined the International Classification of Disease 10th revision code with IBD‐specific medications had the best performance characteristics among the 12 tested definitions. During the 8‐year study period, IBD prevalence increased from 25 345 in 2009 to 47 444 in 2016. Over that period, the prevalence of Crohn's disease increased 1.9‐fold (from 16.0/100 000 in 2009 to 29.6/100 000 in 2016) and that of ulcerative colitis increased 1.6‐fold (from 41.4/100 000 in 2009 to 66.0/100 000 in 2016). Similarly, the estimated incidence of Crohn's disease also increased 1.2‐fold (from 2.4 to 2.9 per 100 000) and that of ulcerative colitis rose 1.3‐fold (from 4.0 to 5.3 per 100 000). During the study period, the predominant increase in IBD incidence was among younger individuals, especially those aged < 30 years. Conclusion Patients with IBD can be accurately identified using Korean insurance claims data by combining information regarding the International Classification of Disease 10th revision codes and the IBD medications used. The prevalence of IBD continues to increase, with an apparent shift toward younger (< 30 years) age groups.

show abstract

Inflammatory Bowel Diseases

Matuchansky¹

2022

Sex/Gender-Specific Medicine in the Gastrointestinal Diseases

View full text Add to dashboard Cite

Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study

Abstract: The recent incidence of IBD in South Korea has been the highest in East Asia. Patients who had been diagnosed recently with IBD showed lower rates of surgery and higher rates of immunomodulator and biologic use compared to those reported ever in South Korea.

Cited by 62 publications

References 34 publications

Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases

Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases

Emerging trends of inflammatory bowel disease in South Korea: A nationwide population‐based study

Inflammatory Bowel Diseases

Contact Info

Product

Resources

About